novakexterior

Wendy Novak Diabetes Institute

NCH logo

411 E Chestnut St
Louisville, KY 40202
Estados Unidos

The Wendy Novak Diabetes Institute, part of Norton Children’s and affiliated with the University of Louisville School of Medicine, is one of the major TrialNet Affiliates at the forefront of type 1 diabetes research. Led by Kupper Wintergerst MD, the TrialNet team at the Wendy Novak Diabetes Institute is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Nuestro Equipo

wintergest

Kupper Wintergerst, MD

Director

Kupper A. Wintergerst, M.D., earned his medical degree from the University of Louisville. He completed his residency in pediatrics at the University of Florida College of Medicine and a fellowship in pediatric endocrinology at Stanford University School of Medicine in California. Dr. Wintergerst has been instrumental in growing the scope of care for children and adolescents with endocrine conditions. He is executive director of Wendy Novak Diabetes Institute, which was formed to expand clinical care, education and research to serve children and adults living with diabetes. Under Dr. Wintergerst’s leadership, Norton Children’s is recognized as a top program nationally in pediatric diabetes and endocrinology by U.S. News & World Report. Dr. Wintergerst is involved in international research efforts focused on diabetes mellitus, with the goals of improving life for patients, preventing the disease and, ultimately, curing Type 1 diabetes. He has been a primary investigator with TrialNet for 13 years.
 

shannon hall

Shannon Hall, BSN, RN

Clinical Research Coordinator

Gwen Pierce, MSN, RN, CCRC

Clinical Research Coordinator

Estudios de Investigación

Risk Screening Risk Screening for Relatives

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Long Term Long-Term Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More

Newly Diagnosed JAK Inhibitors Newly Diagnosed Study (JAKPOT T1D)

TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Detalles